Heart valve engineering: decellularized allograft matrices in clinical practice

References

[1] Baraki H, Tudorache I, Braun M, et al. Orthotopic replacement of the aortic valve with decellularized allograft in a sheep model. Biomaterials 2009; 30: 6240–6246.10.1016/j.biomaterials.2009.07.068Search in Google Scholar PubMed

[2] Bechtel JF, Stierle U, Sievers HH. Fifty-two months’ mean follow-up of decellularized SynerGraft-treated pulmonary valve allografts. J Heart Valve Dis 2008; 17: 98–104; discussion 104.Search in Google Scholar

[3] Brown JW, Elkins RC, Clarke DR, et al. Performance of the cryovalve SG human decellularized pulmonary valve in 342 patients relative to the conventional cryovalve at a mean follow-up of four years. J Thorac Cardiovasc Surg 2010; 139: 339–348.10.1016/j.jtcvs.2009.04.065Search in Google Scholar PubMed

[4] Brown JW, Ruzmetov M, Eltayeb O, Rodefeld MD, Turrentine MW. Performance of SynerGraft decellularized pulmonary homograft in patients undergoing a ross procedure. Ann Thorac Surg 2011; 91: 416–422; discussion 422–413.10.1016/j.athoracsur.2010.10.069Search in Google Scholar PubMed

[5] Burch PT, Kaza AK, Lambert LM, Holubkov R, Shaddy RE, Hawkins JA. Clinical performance of decellularized cryopreserved valved allografts compared with standard allografts in the right ventricular outflow tract. Ann Thorac Surg 2010; 90: 1301–1305; discussion 1306.10.1016/j.athoracsur.2010.05.024Search in Google Scholar PubMed

[6] Cebotari S, Lichtenberg A, Tudorache I, et al. Clinical application of tissue engineered human heart valves using autologous progenitor cells. Circulation 2006; 114: I132–I137.10.1161/CIRCULATIONAHA.105.001065Search in Google Scholar PubMed

[7] Cebotari S, Mertsching H, Kallenbach K, et al. Construction of autologous human heart valves based on an acellular allograft matrix. Circulation 2002; 106: I63–I68.10.1161/01.cir.0000032900.55215.85Search in Google Scholar

[8] Cebotari S, Tudorache I, Ciubotaru A, et al. Use of fresh decellularized allografts for pulmonary valve replacement may reduce the reoperation rate in children and young adults: early report. Circulation 2011; 124: S115–S123.10.1161/CIRCULATIONAHA.110.012161Search in Google Scholar PubMed

[9] Cebotari S, Tudorache I, Jaekel T, et al. Detergent decellularization of heart valves for tissue engineering: toxicological effects of residual detergents on human endothelial cells. Artif Organs 2010; 34: 206–210.10.1111/j.1525-1594.2009.00796.xSearch in Google Scholar PubMed

[10] Cicha I, Ruffer A, Cesnjevar R, et al. Early obstruction of decellularized xenogenic valves in pediatric patients: involvement of inflammatory and fibroproliferative processes. Cardiovasc Pathol 2011; 20: 222–231.10.1016/j.carpath.2010.04.006Search in Google Scholar PubMed

[11] Da Costa FD, Costa AC, Prestes R, et al. The early and midterm function of decellularized aortic valve allografts. Ann Thorac Surg 2010; 90: 1854–1860.10.1016/j.athoracsur.2010.08.022Search in Google Scholar PubMed

[12] Da Costa FD, Dohmen PM, Duarte D, et al. Immunological and echocardiographic evaluation of decellularized versus cryopreserved allografts during the ross operation. Eur J Cardiothorac Surg 2005; 27: 572–578.10.1016/j.ejcts.2004.12.057Search in Google Scholar PubMed

[13] Da Costa FD, Santos LR, Collatusso C, et al. Thirteen years’ experience with the ross operation. J Heart Valve Dis 2009; 18: 84–94.Search in Google Scholar

[14] Dijkman PE, Driessen-Mol A, Frese L, Hoerstrup SP, Baaijens FP. Decellularized homologous tissue-engineered heart valves as off-the-shelf alternatives to xeno- and homografts. Biomaterials 2012; 33: 4545–4554.10.1016/j.biomaterials.2012.03.015Search in Google Scholar PubMed

[15] Dohmen PM, da Costa F, Yoshi S, et al. Histological evaluation of tissue-engineered heart valves implanted in the juvenile sheep model: is there a need for in-vitro seeding? J Heart Valve Dis 2006; 15: 823–829.Search in Google Scholar

[16] Emmert MY, Weber B, Wolint P, et al. Stem cell-based transcatheter aortic valve implantation: first experiences in a pre-clinical model. JACC Cardiovasc Interv 2012; 5: 874–883.10.1016/j.jcin.2012.04.010Search in Google Scholar PubMed

[17] Gerson CJ, Elkins RC, Goldstein S, Heacox AE. Structural integrity of collagen and elastin in SynerGraft® decellularized-cryopreserved human heart valves. Cryobiology 2012; 64: 33–42.10.1016/j.cryobiol.2011.11.001Search in Google Scholar PubMed

[18] Hoerstrup SP, Cummings Mrcs I, Lachat M, et al. Functional growth in tissue-engineered living, vascular grafts: follow-up at 100 weeks in a large animal model. Circulation 2006; 114: I159–I166.10.1161/CIRCULATIONAHA.105.001172Search in Google Scholar PubMed

[19] Kasimir MT, Rieder E, Seebacher G, et al. Decellularization does not eliminate thrombogenicity and inflammatory stimulation in tissue-engineered porcine heart valves. J Heart Valve Dis 2006; 15: 278–286; discussion 286.Search in Google Scholar

[20] Kneib C, von Glehn CQ, Costa FD, Costa MT, Susin MF. Evaluation of humoral immune response to donor HLA after implantation of cellularized versus decellularized human heart valve allografts. Tissue Antigens 2012; 80: 165–174.10.1111/j.1399-0039.2012.01885.xSearch in Google Scholar PubMed

[21] Konuma T, Devaney EJ, Bove EL, et al. Performance of cryovalve sg decellularized pulmonary allografts compared with standard cryopreserved allografts. Ann Thorac Surg 2009; 88: 849–854; discussion 554–845.10.1016/j.athoracsur.2009.06.003Search in Google Scholar PubMed

[22] Lichtenberg A, Tudorache I, Cebotari S, et al. Preclinical testing of tissue-engineered heart valves re-endothelialized under simulated physiological conditions. Circulation 2006; 114: I559–I565.10.1161/CIRCULATIONAHA.105.001206Search in Google Scholar PubMed

[23] Lutter G, Metzner A, Jahnke T, et al. Percutaneous tissue-engineered pulmonary valved stent implantation. Ann Thorac Surg 2010; 89: 259–263.10.1016/j.athoracsur.2009.06.048Search in Google Scholar PubMed

[24] Mendelson K, Schoen FJ. Heart valve tissue engineering: concepts, approaches, progress, and challenges. Ann Biomed Eng 2006; 34: 1799–1819.10.1007/s10439-006-9163-zSearch in Google Scholar PubMed PubMed Central

[25] Miller DV, Edwards WD, Zehr KJ. Endothelial and smooth muscle cell populations in a decellularized cryopreserved aortic homograft (SynerGraft) 2 years after implantation. J Thorac Cardiovasc Surg 2006; 132: 175–176.10.1016/j.jtcvs.2006.02.038Search in Google Scholar

[26] Mulinari LA, Navarro FB, Pimentel GK, et al. The use and midium-term evaluation of decellularized allograft cusp in the surgical treatment of the tetralogy of fallot. Rev Bras Cir Cardiovasc 2008; 23: 197–203.10.1590/S0102-76382008000200008Search in Google Scholar

[27] Narine K, Ing EC, Cornelissen M, et al. Readily available porcine aortic valve matrices for use in tissue valve engineering. Is cryopreservation an option? Cryobiology 2006; 53: 169–181.Search in Google Scholar

[28] Rieder E, Seebacher G, Kasimir MT, et al. Tissue engineering of heart valves: decellularized porcine and human valve scaffolds differ importantly in residual potential to attract monocytic cells. Circulation 2005; 111: 2792–2797.10.1161/CIRCULATIONAHA.104.473629Search in Google Scholar

[29] Ruffer A, Purbojo A, Cicha I, et al. Early failure of xenogenous de-cellularised pulmonary valve conduits – a word of caution! Eur J Cardiothorac Surg 2010; 38: 78–85.10.1016/j.ejcts.2010.01.044Search in Google Scholar

[30] Ruzmetov M, Shah JJ, Geiss DM, Fortuna RS. Decellularized versus standard cryopreserved valve allografts for right ventricular outflow tract reconstruction: a single-institution comparison. J Thorac Cardiovasc Surg 2012; 143: 543–549.10.1016/j.jtcvs.2011.12.032Search in Google Scholar

[31] Schmidt D, Dijkman PE, Driessen-Mol A, et al. Minimally-invasive implantation of living tissue engineered heart valves: a comprehensive approach from autologous vascular cells to stem cells. J Am Coll Cardiol 2010; 56: 510–520.10.1016/j.jacc.2010.04.024Search in Google Scholar

[32] Sharp MA, Phillips D, Roberts I, Hands L. A cautionary case: the SynerGraft vascular prosthesis. Eur J Vasc Endovasc Surg 2004; 27: 42–44.10.1016/j.ejvs.2003.09.015Search in Google Scholar

[33] Simon P, Kasimir MT, Seebacher G, et al. Early failure of the tissue engineered porcine heart valve SynerGraft in pediatric patients. Eur J Cardiothorac Surg 2003; 23: 1002–1006; discussion 1006.10.1016/S1010-7940(03)00094-0Search in Google Scholar

[34] Stock UA, Degenkolbe I, Attmann T, Schenke-Layland K, Freitag S, Lutter G. Prevention of device-related tissue damage during percutaneous deployment of tissue-engineered heart valves. J Thorac Cardiovasc Surg 2006; 131: 1323–1330.10.1016/j.jtcvs.2006.01.053Search in Google Scholar PubMed

[35] Tavakkol Z, Gelehrter S, Goldberg CS, Bove EL, Devaney EJ, Ohye RG. Superior durability of SynerGraft pulmonary allografts compared with standard cryopreserved allografts. Ann Thorac Surg 2005; 80: 1610–1614.10.1016/j.athoracsur.2005.04.017Search in Google Scholar PubMed

[36] Tudorache I, Calistru A, Baraki H, et al. Orthotopic replacement of aortic heart valves with tissue engineered grafts. Tissue Eng A 2013 April 26 [Epub ahead of print].10.1089/ten.tea.2012.0074Search in Google Scholar PubMed PubMed Central

[37] Wollmann LC, Laurindo CA, Costa FD, Moreno AN. Effects of cryopreservation and/or decellularization on extracellular matrix of porcine valves. Rev Bras Cir Cardiovasc 2011; 26: 490–496.10.5935/1678-9741.20110029Search in Google Scholar PubMed

[38] Zehr KJ, Yagubyan M, Connolly HM, Nelson SM, Schaff HV. Aortic root replacement with a novel decellularized cryopreserved aortic homograft: postoperative immunoreactivity and early results. J Thorac Cardiovasc Surg 2005; 130: 1010–1015.10.1016/j.jtcvs.2005.03.044Search in Google Scholar PubMed

[39] Zhou J, Fritze O, Schleicher M, et al. Impact of heart valve decellularization on 3-D ultrastructure, immunogenicity and thrombogenicity. Biomaterials 2010; 31: 2549–2554.10.1016/j.biomaterials.2009.11.088Search in Google Scholar PubMed